Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2012

Is Methylphenidate Transdermal System
(Daytrana®) Safe and Effective for Managing
Attention Deficit Hyperactivity Disorder
Symptoms in Children?
Pamela Cassidy
Philadelphia College of Osteopathic Medicine, pamelaca@pcom.edu

Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Child Psychology Commons, and the Medical Pharmacology Commons
Recommended Citation
Cassidy, Pamela, "Is Methylphenidate Transdermal System (Daytrana®) Safe and Effective for Managing Attention Deficit
Hyperactivity Disorder Symptoms in Children?" (2012). PCOM Physician Assistant Studies Student Scholarship. Paper 91.

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Is Methylphenidate Transdermal System (Daytrana®) Safe and
Effective for Managing Attention Deficit Hyperactivity Disorder
Symptoms in Children?

Pamela Cassidy, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirements For
The Degree of Master of Science
In
Health Sciences – Physician Assistant
Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania
February 9, 2012

ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
methylphenidate transdermal system (Daytrana®) is safe and effective for managing attention
deficit hyperactivity disorder symptoms in children.
STUDY DESIGN: A review of three English language studies published from 2006-2010.
Includes two randomized, double-blind, controlled trials and one randomized, controlled
crossover study.
DATA SOURCES: Randomized, placebo-controlled studies evaluating the effectiveness and
safety of methylphenidate transdermal system (MTS) for managing attention deficit
hyperactivity disorder (ADHD) symptoms in children were located using the PubMed, CINAHL,
and Cochrane Library databases.
OUTCOMES MEASURED: The primary measures of effectiveness used were the ADHD
Rating Scale IV and SKAMP Teacher Rating Scale. The secondary measures of effectiveness
were the Clinical Global Impressions-Improvement Scale and Parent’s Global Assessment. The
measures of safety included adverse events (headache, anorexia, insomnia, gastrointestinal
symptoms, abdominal pain, dizziness, etc.), skin reactions, vital signs, physical exam findings,
EKG findings, and laboratory values.
RESULTS: Three randomized, controlled studies comparing MTS to a placebo transdermal
patch were reviewed. All three studies found a statistically significant difference between the two
treatment groups in the efficacy measurement scales, with evident improvement noted in MTS
participants versus placebo. All three studies also found MTS to be well tolerated. The majority
of adverse events were mild to moderate, and the most common events were decreased appetite,
headache, gastrointestinal symptoms, and insomnia.
CONCLUSIONS: The results of all three studies in this review support a similar conclusion, that
MTS is both effective and safe in the treatment of children 6-12 years of age diagnosed with
ADHD. MTS provides the first non-oral administration of stimulant medication in the treatment
of ADHD.
KEY WORDS: Transdermal methylphenidate, ADHD.
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INTRODUCTION
Attention deficit hyperactivity disorder (ADHD) is a serious neurobehavioral disorder
associated with persistent inattention, hyperactivity, and impulsivity. ADHD is one of the most
common neurobehavioral disorders in youth and often leads to significant academic, home, and
social impairments. In the US, the estimated prevalence of ADHD in school-age children is 37%, and the annual societal “cost of illness” of ADHD is estimated between $36 and $52 billion
(2005).1 ADHD is a significant financial burden due to the cost of medical care and work loss for
patients and family members. The cost annually per individual in 2005 was estimated between
$12,005 and $17,458, and there were an estimated 7 million ambulatory care visits in 2006 for
ADHD.1
ADHD is a complex disorder and can have multiple effects on a child’s development.
Children with ADHD have difficulty with friendships and peer relationships, are at increased risk
of more frequent and serious injuries, and struggle with school work, resulting in lower grades.1
ADHD also increases the risk for various comorbidities, such as a learning disability,
oppositional defiant or conduct disorder, anxiety, depression, and Tourette syndrome.2 In
addition, the majority of children with ADHD continue to have symptoms and the associated
impairments of the disorder into adolescence and adulthood. Thus, the diagnosis of ADHD in a
child has significant meaning, and physician assistants, regardless of the specialty they may
practice in, are bound to encounter patients and families affected by ADHD.
The causes and risk factors for ADHD remain unknown, but current research suggests a
genetic component. Recent studies of twins demonstrate a relationship between ADHD and
genes, however, like many other conditions, ADHD likely results from a combination of factors.3
Researchers are studying the link of environmental factors (lead exposure, tobacco and alcohol
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use during pregnancy, premature delivery), traumatic brain injuries, and food additives to the
development of ADHD.1,2 A once popular belief that refined sugar causes or worsens ADHD
symptoms has since been disproven by numerous studies.2
The treatment of ADHD is individualized and multifactorial, including medications,
behavioral intervention strategies, and training for parents and teachers. Stimulant medications
are the most widely used method to treat ADHD and are considered first-line medical treatment.
Seventy to eighty percent of children respond positively to stimulant medication, which has been
used for more than 60 years. Stimulants do not cure ADHD, but instead control the symptoms of
inattention, hyperactivity, and impulsivity. Stimulants are available in immediate- and extendedrelease formulations. Immediate-release stimulants require frequent doses and may lead to
decreased compliance, lack of privacy, and fear with in-school doses.
This review examines methylphenidate transdermal system (MTS), a discrete, colorless
patch. It is the only non-oral medication approved specifically for the treatment of ADHD and
provides an option for patients who have difficulty swallowing or tolerating oral medications or
for those who need improved control of the duration of medication effect.7 The once-daily
application provides continuous, consistent delivery of methylphenidate for the standard ninehour wear time. The transdermal delivery bypasses the first-pass metabolism in the liver, so more
methylphenidate is available in the body. MTS offers a unique, new ADHD treatment option.

OBJECTIVE
The objective of this selective EBM review is to determine whether or not
methylphenidate transdermal system (Daytrana®) is safe and effective for managing attention
deficit hyperactivity disorder symptoms in children.
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METHODS
The three studies in this review were researched by the author using PubMed, CINAHL,
and Cochrane Library databases using the following keywords: transdermal methylphenidate,
ADHD. All articles were published in English, in peer-reviewed journals, and selected by the
author based on relevance and significance of the outcomes to patients. Inclusion criteria were
randomized, controlled studies published after 1996, children aged 6-12 years diagnosed with
ADHD by the Diagnostic and Statistical Manual of Mental Disorders IV criteria, and patientoriented outcomes. Patients outside of the 6-12 year age range or with comorbid psychiatric
disorders, concurrent illness or skin disorder, or mental retardation were excluded.
This review includes two randomized controlled trials and one randomized, controlled
crossover study, all of which compared the methylphenidate transdermal system to a placebo
patch. The outcomes measured include the effects of MTS on ADHD symptoms and severity,
and the safety of the transdermal patch. The studies reported statistical summaries with the
following: mean change from baseline, confidence interval (CI), p-value, F-value, number
needed to treat (NNT), and number needed to harm (NNH). Demographics and characteristics of
the specific studies are found in Table 1.
Table 1. Demographics & Characteristics of Included Studies
Study

Type

Findling et
al, 2008.4

Doubleblind RCT.

#
Pts
274

Age
(yrs)
6-12

Inclusion
Criteria
ADHD
diagnosis;
responsive or
naïve to
stimulants; IQ
>80; ADHD
Rating Scale
score >26;
normal lab
parameters and
vital signs.

Exclusion Criteria

W/D

Interventions

Comorbid
psychiatric
disorders; history
of seizures, tics, or
skin disorders; use
of clonidine,
antidepressants,
hepatic enzyme
altering agents,
sedatives, or
antipsychotics in
past 30 days.

105

MTS – 2
weeks at pt’s
optimized
dose (10, 15,
20, or 30 mg);
delivered over
9-hour wear
time.
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McGough
et al, 2006.5

Doubleblind RCT.

93

6-12

ADHD
diagnosis;
responsive or
naïve to
stimulants; IQ
>80; ADHD
Rating Scale
score >26;
normal
laboratory
parameters and
vital signs.

Comorbid
psychiatric
disorders; history
of seizures, tics, or
skin disorders;
mental retardation;
use of clonidine,
antidepressants,
hepatic enzyme
altering agents,
sedatives, or
antipsychotics in
past 30 days.

13

MTS – 1
week at pt’s
optimized
dose (10, 16,
20, or 27 mg);
delivered over
9-hour wear
time.

Wilens et
al, 2010.6

Randomized,
controlled,
crossover
study.

36

6-12

ADHD
diagnosis and a
clinical
psychiatric
interview.

Dermatologic
atopy; structural
cardiac defects; IQ
<70; seizure or
psychological
disorder; history
of no response or
intolerable adverse
effects to
methylphenidate.

10

MTS – 10 or
20 mg;
delivered over
9-hour wear
time.

OUTCOMES MEASURED
The outcomes measured in the three studies were patient oriented and included the effects
of MTS on ADHD symptoms and the safety of the transdermal patch. The primary measures of
effectiveness were the ADHD Rating Scale IV (Findling et al4, Wilens et al6) and SKAMP
Teacher Rating Scale (McGough et al5). The ADHD Rating Scale is an 18-item scale linked
directly to DSM-IV ADHD diagnostic criteria and used for diagnosing ADHD and assessing the
response to treatment. The SKAMP Teacher Rating Scale is a 15-item scale describing typical
behaviors in a classroom setting; items are rated on a 7-point impairment scale. The secondary
measures of effectiveness were the Clinical Global Impressions-Improvement Scale, a 3-item
observer-rated scale to measure the overall severity and improvement of the patient (Findling et
al4, McGough et al5, Wilens et al6), and the Parent’s Global Assessment, a parent measurement
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of the overall severity and improvement of ADHD in the patient (Findling et al4, McGough et
al5).
In all three studies, the safety of MTS was measured by adverse events (headache,
anorexia, insomnia, gastrointestinal symptoms, abdominal pain, dizziness, etc.), skin reactions,
vital signs, physical exam findings, EKG findings, and laboratory values. These events were
spontaneously reported by the participant or noted at the study visits.

RESULTS
This review includes two randomized controlled trials and one randomized, controlled
crossover study, all of which compared methylphenidate transdermal system to a placebo patch,
and all analyses were intention-to-treat. In all three studies, the patches were applied on the
child’s hip between 6-7 am, alternating sides so that the same application site was not used for
two consecutive days, and worn for approximately nine hours daily. All studies included children
6-12 years of age diagnosed with ADHD by the Diagnostic and Statistical Manual of Mental
Disorders IV criteria because MTS was at the time FDA-approved only for persons six years of
age or older, and children are the population most affected by ADHD. Children with comorbid
conditions or mental retardation were excluded from the studies to specifically look at the
efficacy of MTS on ADHD only. Children with any concurrent illness or skin disorder were also
excluded from all studies because those factors may have compromised safety or study
assessments. All three studies recorded medical compliance at 80%-100% for all subjects by
counting both the used and unused patches at each follow-up visit.4,5,6
Findling et al and Wilens et al used the ADHD Rating Scale (ADHD-RS) as the primary
measure of efficacy, recorded at baseline and then weekly thereafter until the end of the study.
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Findling et al found the ADHD-RS mean total scores were rather severe and similar at baseline,
but not at endpoint (Table 2). Compared to the placebo, the MTS treatment group showed
significant improvements in the change in ADHD-RS mean total scores from baseline to study
endpoint (95% CI = -18.062 to -9.724).4 There was a roughly 2-fold greater improvement in
ADHD symptoms in those treated with MTS compared to placebo.4 Wilens et al also found a
clinically and statistically significant effect of MTS on ADHD symptoms compared to a placebo
using the ADHD-RS at baseline and study endpoint (Table 2). Compared to baseline, there was a
25% reduction of ADHD-RS mean total scores in the placebo group and a 61% reduction in
MTS treatment group.
Table 2. ADHD-RS Mean Total Scores
Study
Findling et al4:
Wilens et al6:

Baseline Score
(MTS; Placebo)
43.0; 41.9
37.80 + 9.08;
37.80 + 9.08

Endpoint Score
(MTS; Placebo)
18.8; 32.1
14.76 + 14.48;
28.33 + 15.75

Change from Baseline
(MTS; Placebo)
-24.2; -10.3
61%; 25% reduction

p-value
p < 0.0001
p < 0.001

McGough et al used the SKAMP Teacher Rating Scale as the primary measure of
efficacy and analyzed the results with analysis of variance and least square mean. The teacher
measured the subject’s deportment (SKAMP-D score) and attention (SKAMP-A score) at
multiple time points during the laboratory classroom sessions of the study. At all individual
postdose time points measured, the mean SKAMP-D scores were considerably lower (i.e.
improved) for MTS than the placebo group and statistically significant. Table 3 demonstrates
that the least square mean for the SKMAP-D scores in the MTS treatment group was
significantly lower than that for the placebo patch treatment group. Analysis of the SKAMP-A
scores showed similar results, as seen below in Table 3.
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Table 3. SKAMP Teacher Rating Scores5
F-score
SKAMP-Deportment
SKAMP-Attention

F(1,77) = 71.48
F(1,77) = 83.04

Least Square Mean,
MTS
3.2 + 0.58
6.2 + 0.50

Least Square Mean,
Placebo
8.0 + 0.58
9.9 + 0.50

p-value
p < 0.0001
p < 0.0001

All three studies used the Clinical Global Impressions-Improvement Scale (CGI-I), a 3item observer-rated scale used to measure the overall severity and improvement of the patient.
The CGI-I score was recorded in both the MTS and placebo treatment groups at the start and end
of the study. These scores were dichotomized into two groups, where group one included very
much improved and much improved and group two included the remaining levels. As seen in
Table 4, all studies found a statistically significantly greater proportion of MTS subjects were
rated as improved, compared with placebo. All three studies also determined the number needed
to treat to produce one additional good outcome was only two patients. Furthermore, two of the
studies (Findling et al4, McGough et al5) used the Parent’s Global Assessment (PGA) and found
similar results after dichotomizing the data (Table 5). The results of all three studies support that
MTS is not only effective in reducing the severity of symptoms based on an ADHD rating scale,
but also produces a noticeable improvement in the patient by observers, teachers, and parents.
Table 4. Clinical Global Impressions-Improvement Scale Scores
Study
Findling et al4
McGough et al5
Wilens et al6

% Improved
(MTS; Placebo)
71.9%; 23.5%
79.8%; 11.6%
83%; 30%

RBI

ABI

NNT

p-value

2.1%
5.9%
1.76%

48.4%
68.2%
53%

2 patients
2 patients
2 patients

p < 0.0001
p < 0.0001
p < 0.0001

RBI (relative benefit increase), ABI (absolute benefit increase), NNT (number needed to treat).
Table 5. Parent’s Global Assessment Scores
Study
Findling et al4
McGough et al5

% Improved
(MTS; Placebo)
69.8%; 24.7%
71.1%; 15.8%

RBI

ABI

NNT

p-value

1.8%
3.5%

24.7%
55.3%

4 patients
2 patients

p < 0.0001
p < 0.0001

RBI (relative benefit increase), ABI (absolute benefit increase), NNT (number needed to treat).
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All three studies examined the safety of MTS compared to a placebo patch and found
MTS to be well tolerated overall. Findling et al and McGough et al both demonstrated no serious
adverse events, including deaths or suicides, with >99% of adverse events classified as mild to
moderate.4,5 The most common adverse events across all studies were decreased appetite,
headache, gastrointestinal problems (nausea, vomiting, abdominal pain), and insomnia.4,5,6 All
three studies found the absolute number of reported events higher for the MTS group. Findling et
al used a post-hoc analysis to find this difference to be statistically insignificant for the ten most
common adverse events. Whereas Wilens et al found a significant increased number of MTS
subjects with loss of appetite compared to placebo (MTS 13%, PTS 0%, x2 12.25, p<0.001).
Table 6 displays the number needed to harm for each study reviewed and were calculated with
different adverse events for each study. The values in Table 6 for Findling et al and McGough et
al used patients with one or more adverse event, whereas the Wilens et al study used patients
with loss of appetite, which was the most common side effect and occurred in 13% of MTS
patients and 0% of placebo patients. Wilens et al determined the number needed to harm with
appetite loss was only two patients. All studies noted that the effects were known adverse effects
of methylphenidate and transdermal applications.
Table 6. Adverse Events – Number Needed to Harm
Study
Findling et al4
McGough et al5
Wilens et al6

RRI
0.3%
0.33%
43/0

ARI
17.9%
7.5%
43%

NNH
6 patients
13 patients
2 patients

p-value
n/a
n/a
p < 0.001

RRI (relative risk increase), ARI (absolute risk increase), NNH (number needed to harm).
Of the three studies reviewed, Findling et al recorded the most detailed dermal response
to the transdermal applications. Findling et al scored dermal effects from zero to seven, ranging
from none to vesicular eruption to strong reaction spreading beyond test site. The highest score
reported for MTS was 4, definite edema, compared to a 3, erythema and papules, for placebo.4
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Also, in both treatment groups 97.7% subjects reported no discomfort (87.3%) or minimal
discomfort (10.4%).4 In addition, McGough et al noted patch adhesion to very good as >90% of
patch surface was judge adhered to the skin for most (86%) patches by the end of the day.
Findling et al had similar results, where 63.2% of subjects had >90% of the patch attached after
nine hours of wear time. Lastly, all studies found no clinically significant effects of MTS on
mean vital signs and other clinical parameters (i.e. EKG findings, laboratory values).

DISCUSSION
This review supports the use of MTS as a safe and effective treatment option for children
6-12 years of age diagnosed with ADHD. MTS was the first non-oral medication FDA-approved
for the treatment of ADHD in persons 6-12 years in April 2006, and is now approved and proven
effective for use in adolescents 13-17 years of age.7,8 Additional research is required to examine
the use of MTS in adults.
MTS is a valuable option for treatment of ADHD, however as with every medication,
there are warnings and contradictions for its use. MTS is a schedule II controlled substance, as
are other methylphenidate products, because it can be abused or lead to dependence. MTS should
be given cautiously to patients with a history of drug dependence or alcoholism.9
Contraindications to MTS include patients with a known hypersensitivity to methylphenidate,
acrylic adhesive, or silicone adhesive (does not contain latex); marked anxiety, tension, and
agitation; glaucoma; motor tics or family history of Tourette syndrome; or are being treated with
monoamine oxidase inhibitors. MTS should only be prescribed for the treatment of ADHD in
patients 6-17 years of age.
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MTS is a central nervous system stimulant, as are all the stimulant medications for
ADHD, and associated with the risk of cardiovascular side effects. Sudden death has been
reported with the use of CNS stimulants at usual doses in children, adolescents, and adults.
Therefore, stimulant products should not be used in patients with known structural cardiac
abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or
other serious heart problems.9 In this review, no significant cardiovascular events related to
treatment, no clinically significant changes from baseline EKG findings, and no reports of death
were observed.
A limitation of this review is that it only examines the use of MTS in children 6-12 years
of age, and MTS is now FDA-approved for up to age 17 years, as of July 20108. Looking ahead,
studies investigating the use of MTS in adults would be beneficiary. Another limitation of this
review is that all three studies involved relatively small sample sizes that were predominately
white males with combined ADHD type. So the use of MTS in females, other races, and patients
with only inattentive or hyperactive type is not as specifically studied in this review. An
additional limitation of the studies included in this review is that the participants who were
withdrawn from the studies were not specifically analyzed. Findling et al had the largest number
of withdrawn patients at 105 due to various reasons after receiving the double-blind medication.
McGough et al had 13 patients withdrawn prior to randomization and Wilens et al had 10
patients withdrawn. All three studies reported adverse events, protocol violation, withdrawn
consent or lost to follow-up as reasons for withdrawn participants.
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CONCLUSION
This review of three randomized, controlled studies determined methylphenidate
transdermal system to be safe and effective for managing ADHD symptoms in children 6-12
years of age. MTS provides children diagnosed with ADHD, and their parents and medical
providers, with a new treatment option. Future research should be designed to examine the
effects of MTS in older patients, as well as how its efficacy compares to oral stimulant
medication for ADHD. The focus of this review was whether or not MTS is safe and effective,
and additional research evaluating the optimal dose and wear time of MTS is necessary. Also,
because of the high rates of comorbidities in patients diagnosed with ADHD, future research is
needed to study the effects of MTS in patients with coexisting illnesses. Despite the need for
additional studies, methylphenidate transdermal system remains a safe and effective, once-daily
administration of stimulant medication for children diagnosed with attention deficit hyperactivity
disorder.
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